Open AccessHLA Mismatches Remain Risk Factors for Acute Kidney Allograft Rejection in Patients Receiving Quadruple Immunosuppression With Anti-Interleukin-2 Receptor Antibodies
Author(s) -
Karl Martin Wissing,
Guy Fomegne,
Nilüfer Broeders,
Lidia Ghisdal,
Anh Dung Hoang,
Dimitri Mikhalski,
Vincent Donckier,
Pierre Vereerstraeten,
Daniel Abramowicz
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31816349b5
Subject(s) - medicine , daclizumab , basiliximab , tacrolimus , immunosuppression , calcineurin , transplantation , dialysis , kidney transplantation , panel reactive antibody , belatacept , mycophenolic acid , human leukocyte antigen , immunology , gastroenterology , antigen , kidney transplant
New immunosuppressive drugs such as anti-interleukin-2 receptor antibodies (aIL2R) and mycophenolate mofetil (MMF) have reduced the incidence of acute rejection after renal transplantation. Whether matching donor and recipient human leukocyte antigen (HLA) antigens is still relevant in patients receiving modern immunosuppression has been questioned.